Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
7
GOVX Quote, Financials, Valuation and Earnings
Last price:
$3.03
Seasonality move
:
-11.34%
Day range:
$2.81 - $3.14
52-week range:
$2.61 - $57.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.08x
P/B ratio:
1.06x
Volume:
238.2K
Avg. volume:
179.4K
1-year change:
-94.66%
Market cap:
$5.2M
Revenue:
$4M
EPS (TTM):
-$1.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
DARE
Daré Bioscience, Inc.
|
$765K | -$0.43 | 2911.81% | -13.48% | $10.75 |
|
HYPD
Hyperion DeFi, Inc.
|
$500K | -- | 1679.36% | -- | $5.88 |
|
OMER
Omeros Corp.
|
-- | $0.16 | -- | -2.38% | $38.00 |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$139.5K | -$0.49 | -40.39% | -5.71% | $0.97 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
$2.99 | $9.63 | $5.2M | -- | $0.00 | 0% | 3.08x |
|
DARE
Daré Bioscience, Inc.
|
$1.93 | $10.75 | $27.6M | 95.38x | $0.00 | 0% | 389.60x |
|
HYPD
Hyperion DeFi, Inc.
|
$3.26 | $5.88 | $26.4M | -- | $0.00 | 0% | 84.50x |
|
OMER
Omeros Corp.
|
$12.01 | $38.00 | $851.5M | -- | $0.00 | 0% | -- |
|
SPRO
Spero Therapeutics, Inc.
|
$2.41 | $4.00 | $135.8M | 10.75x | $0.00 | 0% | 4.57x |
|
VTGN
Vistagen Therapeutics, Inc.
|
$0.66 | $0.97 | $26.2M | -- | $0.00 | 0% | 23.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.979 | -- | 2.75x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.066 | 27.91% | 1.09x |
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 22.776 | 13.53% | 2.04x |
|
OMER
Omeros Corp.
|
254.22% | -2.814 | 126.5% | 0.76x |
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 13.382 | 3.17% | 3.63x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 1.873 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
GeoVax Labs, Inc. vs. Competitors
-
Which has Higher Returns GOVX or DARE?
Daré Bioscience, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of -154904.35%. GeoVax Labs, Inc.'s return on equity of -433.69% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About GOVX or DARE?
GeoVax Labs, Inc. has a consensus price target of $9.63, signalling upside risk potential of 7947.66%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 457%. Given that GeoVax Labs, Inc. has higher upside potential than Daré Bioscience, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Daré Bioscience, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.4 0 0 DAREDaré Bioscience, Inc.3 0 0 -
Is GOVX or DARE More Risky?
GeoVax Labs, Inc. has a beta of 3.675, which suggesting that the stock is 267.454% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.
-
Which is a Better Dividend Stock GOVX or DARE?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or DARE?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Daré Bioscience, Inc. quarterly revenues of $2.3K. GeoVax Labs, Inc.'s net income of -$6.3M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 3.08x versus 389.60x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.3.08x -- -- -$6.3M DAREDaré Bioscience, Inc.389.60x 95.38x $2.3K -$3.6M
-
Which has Higher Returns GOVX or HYPD?
Hyperion DeFi, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of --. GeoVax Labs, Inc.'s return on equity of -433.69% beat Hyperion DeFi, Inc.'s return on equity of -143.24%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M HYPDHyperion DeFi, Inc.-- $0.05 $79.2M -
What do Analysts Say About GOVX or HYPD?
GeoVax Labs, Inc. has a consensus price target of $9.63, signalling upside risk potential of 7947.66%. On the other hand Hyperion DeFi, Inc. has an analysts' consensus of $5.88 which suggests that it could grow by 80.22%. Given that GeoVax Labs, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.4 0 0 HYPDHyperion DeFi, Inc.2 0 0 -
Is GOVX or HYPD More Risky?
GeoVax Labs, Inc. has a beta of 3.675, which suggesting that the stock is 267.454% more volatile than S&P 500. In comparison Hyperion DeFi, Inc. has a beta of 2.689, suggesting its more volatile than the S&P 500 by 168.937%.
-
Which is a Better Dividend Stock GOVX or HYPD?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hyperion DeFi, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Hyperion DeFi, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or HYPD?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Hyperion DeFi, Inc. quarterly revenues of $302.5K. GeoVax Labs, Inc.'s net income of -$6.3M is lower than Hyperion DeFi, Inc.'s net income of $6.6M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Hyperion DeFi, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 3.08x versus 84.50x for Hyperion DeFi, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.3.08x -- -- -$6.3M HYPDHyperion DeFi, Inc.84.50x -- $302.5K $6.6M
-
Which has Higher Returns GOVX or OMER?
Omeros Corp. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of --. GeoVax Labs, Inc.'s return on equity of -433.69% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About GOVX or OMER?
GeoVax Labs, Inc. has a consensus price target of $9.63, signalling upside risk potential of 7947.66%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 216.4%. Given that GeoVax Labs, Inc. has higher upside potential than Omeros Corp., analysts believe GeoVax Labs, Inc. is more attractive than Omeros Corp..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.4 0 0 OMEROmeros Corp.2 2 0 -
Is GOVX or OMER More Risky?
GeoVax Labs, Inc. has a beta of 3.675, which suggesting that the stock is 267.454% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.380, suggesting its more volatile than the S&P 500 by 138.029%.
-
Which is a Better Dividend Stock GOVX or OMER?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or OMER?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Omeros Corp. quarterly revenues of --. GeoVax Labs, Inc.'s net income of -$6.3M is higher than Omeros Corp.'s net income of -$21.2M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 3.08x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.3.08x -- -- -$6.3M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns GOVX or SPRO?
Spero Therapeutics, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of -242.19%. GeoVax Labs, Inc.'s return on equity of -433.69% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M -
What do Analysts Say About GOVX or SPRO?
GeoVax Labs, Inc. has a consensus price target of $9.63, signalling upside risk potential of 7947.66%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 65.98%. Given that GeoVax Labs, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.4 0 0 SPROSpero Therapeutics, Inc.0 1 0 -
Is GOVX or SPRO More Risky?
GeoVax Labs, Inc. has a beta of 3.675, which suggesting that the stock is 267.454% more volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.062%.
-
Which is a Better Dividend Stock GOVX or SPRO?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or SPRO?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. GeoVax Labs, Inc.'s net income of -$6.3M is higher than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 3.08x versus 4.57x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.3.08x -- -- -$6.3M SPROSpero Therapeutics, Inc.4.57x 10.75x $3M -$7.4M
-
Which has Higher Returns GOVX or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -630.04% compared to GeoVax Labs, Inc.'s net margin of -7525.97%. GeoVax Labs, Inc.'s return on equity of -433.69% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About GOVX or VTGN?
GeoVax Labs, Inc. has a consensus price target of $9.63, signalling upside risk potential of 7947.66%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 45.63%. Given that GeoVax Labs, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GOVXGeoVax Labs, Inc.4 0 0 VTGNVistagen Therapeutics, Inc.0 5 0 -
Is GOVX or VTGN More Risky?
GeoVax Labs, Inc. has a beta of 3.675, which suggesting that the stock is 267.454% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.307, suggesting its less volatile than the S&P 500 by 69.277%.
-
Which is a Better Dividend Stock GOVX or VTGN?
GeoVax Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeoVax Labs, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GOVX or VTGN?
GeoVax Labs, Inc. quarterly revenues are --, which are smaller than Vistagen Therapeutics, Inc. quarterly revenues of $258K. GeoVax Labs, Inc.'s net income of -$6.3M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, GeoVax Labs, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeoVax Labs, Inc. is 3.08x versus 23.30x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GOVXGeoVax Labs, Inc.3.08x -- -- -$6.3M VTGNVistagen Therapeutics, Inc.23.30x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
